195 related articles for article (PubMed ID: 24253338)
1. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging.
Manegold-Brauer G; Bellin AK; Tercanli S; Lapaire O; Heinzelmann-Schwarz V
Arch Gynecol Obstet; 2014 Mar; 289(3):491-8. PubMed ID: 24253338
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
Nam EJ; Yun MJ; Oh YT; Kim JW; Kim JH; Kim S; Jung YW; Kim SW; Kim YT
Gynecol Oncol; 2010 Mar; 116(3):389-94. PubMed ID: 19926121
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer: detection and radiologic staging.
Shaaban A; Rezvani M
Clin Obstet Gynecol; 2009 Mar; 52(1):73-93. PubMed ID: 19179862
[TBL] [Abstract][Full Text] [Related]
4. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization.
Iyer VR; Lee SI
AJR Am J Roentgenol; 2010 Feb; 194(2):311-21. PubMed ID: 20093590
[TBL] [Abstract][Full Text] [Related]
5. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
Dauwen H; Van Calster B; Deroose CM; Op de Beeck K; Amant F; Neven P; Berteloot P; Leunen K; Timmerman D; Vergote I
Gynecol Oncol; 2013 Dec; 131(3):694-700. PubMed ID: 23988417
[TBL] [Abstract][Full Text] [Related]
6. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT as a molecular biomarker in ovarian cancer.
Nowosinska E; Avril S; Murray I; Szyszko T; Avril N
Cancer Biomark; 2010-2011; 8(4-5):167-75. PubMed ID: 22045351
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
9. Imaging techniques for the evaluation of ovarian cancer.
Fischerova D; Burgetova A
Best Pract Res Clin Obstet Gynaecol; 2014 Jul; 28(5):697-720. PubMed ID: 24846098
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography.
Kawahara K; Yoshida Y; Kurokawa T; Suzuki Y; Nagahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
J Comput Assist Tomogr; 2004; 28(4):505-16. PubMed ID: 15232382
[TBL] [Abstract][Full Text] [Related]
11. Radiological assessment of gynecologic malignancies.
Bell DJ; Pannu HK
Obstet Gynecol Clin North Am; 2011 Mar; 38(1):45-68, vii. PubMed ID: 21419327
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
13. PET/CT and cross sectional imaging of gynecologic malignancy.
Iyer RB; Balachandran A; Devine CE
Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S130-8. PubMed ID: 17921092
[TBL] [Abstract][Full Text] [Related]
14. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
Risum S; Høgdall C; Markova E; Berthelsen AK; Loft A; Jensen F; Høgdall E; Roed H; Engelholm SA
Int J Gynecol Cancer; 2009 May; 19(4):600-4. PubMed ID: 19509556
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic imaging in gynecologic malignancy.
Bhosale P; Iyer R
Minerva Ginecol; 2008 Apr; 60(2):143-54. PubMed ID: 18487965
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Takekuma M; Maeda M; Ozawa T; Yasumi K; Torizuka T
Int J Clin Oncol; 2005 Jun; 10(3):177-81. PubMed ID: 15990965
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation.
Kuyumcuoğlu U; Guzel AI; Celik Y; Erdemoğlu M; Komek H
Ginekol Pol; 2011 Aug; 82(8):602-6. PubMed ID: 21957605
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer.
Mironov S; Akin O; Pandit-Taskar N; Hann LE
Radiol Clin North Am; 2007 Jan; 45(1):149-66. PubMed ID: 17157627
[TBL] [Abstract][Full Text] [Related]
19. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography.
Yamamoto Y; Oguri H; Yamada R; Maeda N; Kohsaki S; Fukaya T
Int J Gynaecol Obstet; 2008 Aug; 102(2):124-7. PubMed ID: 18423470
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
